Boehringer Bemoans Medicare Drug Price Talks As 'A Sham'

By Theresa Schliep · September 28, 2023, 7:38 PM EDT

Boehringer Ingelheim Pharmaceuticals Inc. slammed the new Medicare drug price negotiation program in a Connecticut federal court filing as a "sham from beginning to end," even as it indicated Thursday that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al

Case Number

3:23-cv-01103

Court

Connecticut

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

August 18, 2023

Recent Articles By Theresa

July 23, 2024
Kickback Risk Remains For Gene Therapy Fertility Programs
July 16, 2024
No Let-Up On DOJ Medicare Advantage Fraud Probes
July 09, 2024
Jarkesy Decision May Hit Key Healthcare Enforcement Tool
July 02, 2024
4 Takeaways From FDA's Clinical Trial Diversity Guidance
June 28, 2024
Health Regulators Likely To Tread Carefully Post-Chevron
June 25, 2024
Mich. Judge Blocks State Abortion Waiting Period, Counseling
June 25, 2024
In High Court Loss, Anti-Abortion Atty Sees Win For Objectors
June 18, 2024
Prelogar's Mifepristone Win Is 'A Master Class,' Advocates Say
June 13, 2024
Abortion Medication Case Ends 'With A Whimper' At High Court
June 04, 2024
HHS Guidance, Feud Over FCA Evidence, And A Deposed AG